Black Rock Inc. Monopar Therapeutics Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.46 - $7.6 $3,397 - $17,685	-2,327 Closed	0 $0
Q2 2022 Aug 12, 2022	SELL	$1.85 - $2.72 $21,071 - $30,980	-11,390 Reduced 83.04%	2,327 $5,000
Q1 2022 May 12, 2022	SELL	$2.5 - $3.62 $1,395 - $2,019	-558 Reduced 3.91%	13,717 $35,000
Q4 2021 Feb 10, 2022	BUY	$3.17 - $5.24 $982 - $1,624	310 Added 2.22%	14,275 $46,000
Q3 2021 Nov 09, 2021	SELL	$4.5 - $6.0 $4,864 - $6,486	-1,081 Reduced 7.18%	13,965 $68,000
Q2 2021 Aug 11, 2021	BUY	$5.05 - $6.49 $75,982 - $97,648	15,046 New	15,046 $89,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $528M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.